RYK and prostate carcinoma: By analyzing the expression of known WNT5A receptors in five different prostate cancer cell lines, performing functional assays, and validating receptor expression in a large set of human samples, we found the receptors FZD5 and RYK mediate anti-tumor effects of WNT5A in prostate cancer.